Calls for “Structural Policy Changes” for Biosimilars Market

May 01, 2019

The Biosimilars Forum, in partnership with Medicines for Europe, says the U.S. can look to European policy directives to advance the biosimilars market.

5 Myths About Biosimilars-And the Facts

April 15, 2019

The falsehoods being spread about biosimilars that don’t match up with reality.

FDA Issues Biosimilar Naming Guidance

April 01, 2019

The FDA issued a lengthy statement on biosimilar naming conventions-but industry groups worry it could disincentivize biosimilar development.

The Fight to End Misleading Info on Biosimilars

April 01, 2019

Industry groups are calling for clear FDA guidance on language used by biologic originators to protect market share.

The Promise of Specialty Drugs

April 01, 2019

What the future of specialty drugs holds for healthcare.

Novel Therapies Mitigate High-Cost Rheumatoid Arthritis Treatment

March 01, 2019

The latest in RA therapies, and what you can expect from the pipeline.

The Biggest Obstacle to Cancer Biosimilar Development

March 01, 2019

Biosimilar drugs are poised to transform the cancer drug market-so why is uptake so slow?

3 Creative Ways Biologic Innovators Are Protecting Their Turf

March 01, 2019

As more biosimilar agents are approved by the FDA, biologic manufacturers are looking for unique ways to hold on to market share.

The State of Biosimilars in 2019

February 06, 2019

While still largely a new phenomenon, biosimilars are here to stay-and this year will only bring more of them to market.

Top 2 Myths About Biosimilars

February 01, 2019

Biosimilar adoption is not happening as fast as once expected-will fears about future growth hold the market back?